| New online platform to help pharmaceutical companies find, evaluate and manage drug partners |
| 01 May 2009 |
| Thursday, 23 April 2009 var sburl4381 = window.location.href; var sbtitle4381 = do... |
| Read More >> |
| Novartis gains rights to drugs for fatal blood disorders |
| 16 December 2009 |
| Novartis has gained exclusive rights to two therapies for patients with life-threatening cancers and blood disorders. Under a licensing agreement with Incyte Corporation, Novartis will have responsibility for the future development of Incyte's oral targeted investigational JAK inhibitor outside America and for future development o... |
| Read More >> |
| HIV vaccine delivery mechanism successful in tests |
| 16 December 2009 |
| Results of a Phase I clinical trial of a preventive HIV vaccine testing a delivery mechanism called electroporation show that it enhanced the immune responses elicited by the vaccine. The randomised, placebo-controlled trial was conducted by Dr Sandhya Vasan and Dr David Ho of the Aaron Diamond Aids Research Center at the Rockefel... |
| Read More >> |
| API from cow's milk 'could cure most diseases' |
| 09 February 2010 |
| A broad spectrum antiviral and immune modulator branded Receptol could help to cure most of the world's diseases, it has been claimed. Biomix Network, a nano-biotech pharmaceutical company founded in November 1996, is working wi... |
| Read More >> |
| Registration is now live for CPhI South America |
| 04 March 2010 |
| CPhI South America 17 – 19 August 2010 Buenos Aires Argentina With a 15.3% year-on-year growth rate South America belongs to o... |
| Read More >> |
| Exhibit at CPhI Worldwide 2010 |
| 04 March 2010 |
| CPhI Worldwide 2010 5 -7 October 2010 Paris Nord Villepinte, France With a year-on-year increase in visitor attendance, even in tough economic times, CPhI Worldwide is a unique and unrivalled platform for the pharmaceutical ingre... |
| Read More >> |
| New stop-smoking drug trial successful |
| 10 November 2009 |
| Smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who take varenicline are over 33 per cent more likely to quit smoking and remain abstinent than those who do not take the drug, according to a new study. The study results showed that 42.3 per cent of smokers with mild-to-moderate chronic obstructive pulmon... |
| Read More >> |
| Positive thinking: Practice this stress management skill |
| 21 April 2009 |
| Positive thinking helps with stress management and can even improve your health. Overcome negative self-talk by recognizing it and practicing with some examples provided. By Mayo Clinic staff Is your glass half-empty or... |
| Read More >> |
| Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix® |
| 01 May 2009 |
| Pfizer Inc announced the results of a study that found that 47 percent of smokers with a history of cardiovascular disease who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with just 13.9 percent of those given placebo. These findings were pres... |
| Read More >> |
| CPHI Japan - 21-23 April 2010 |
| 09 February 2010 |
| CPHI Japan 21-23 April 2010 Tokyo Big Sight Exhibition Center Are you still in doubt if you should visit CPhI Japan? Do you realise that this is your chance to meet pharma companies from a country known for its leading technologies... |
| Read More >> |
| Scottish leukaemia patients gain access to life-prolonging MabThera |
| 09 February 2010 |
| All patients in Scotland with the most common form of leukaemia now have access to MabThera (rituximab). Scotland is the first country in the UK to make the drug available to chronic lymphocytic leukaemia patients after the Scottish Medicines Consortium (SMC) extended its recommendation. MabThera can now be used by... |
| Read More >> |
| Large project to develop new mental health drugs begins |
| 09 February 2010 |
| A collaboration of scientists has been formed with the aim of discovering new active pharmaceutical ingredients and drugs for the treatment of depression and schizophrenia. Led by research company H Lundbeck A/S and King's College London, the large research academic-industry collaboration project is called Novel Methods leading to... |
| Read More >> |
| Teva announces net sales of $3.55 billion |
| 10 November 2009 |
| Israel-based Teva Pharmaceutical Industries has announced net sales of $3.55 billion (£2.16 billion) in its results for the third quarter of 2009, which ended September 30th. This is a 25 per cent increase on the 2008 third quarter of results released by the global pharmaceutical company, which specialises in the development... |
| Read More >> |
| GSK to improve medicines for those in poorest countries |
| 09 February 2010 |
| GlaxoSmithKline has revealed a series of new initiatives that are aimed at improving the company's delivery of new and better medicines to the diseased in the world's poorest countries. The company is to encourage new research into neglected tropical diseases as well as expanding people in third world countries' access to medicin... |
| Read More >> |
| Tamiflu Approved For Use Against Swine Flu, But Timing Is A Critical Factor In The Drug's Effectiveness, Cautions DoctorSolve |
| 13 May 2009 |
| VANCOUVER, BC, May 06, 2009 /Pharmaceutical News Articles/ -- The swine influenza (H1N1) that has hit Mexico has jumped borders into the US, Canada, Spain, Israel, Britain, Switzerland, Peru, Austria, New Zealand and Germany and is causing many to frantically search for medical protection. The World Health Organization, which has... |
| Read More >> |
| What's new in Magazines? |
| 18 November 2009 |
| Pharmaceutical Technology Europe Pharmaceutical Technology Europe magazine is the market leading publication for European professionals actively involved in pharmaceutical/biopharmaceutical development, manufacturing & QA/QC. Servi... |
| Read More >> |